Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03887494
Other study ID # K171014J
Secondary ID 2018-A01901-54
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date September 6, 2019
Est. completion date June 30, 2020

Study information

Verified date September 2019
Source Assistance Publique - Hôpitaux de Paris
Contact Olivier Pellerin, MD, PhD
Phone +33156092660
Email olivier.pellerin@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Bone metastases appear in many cancers. They are associated with severe pain that is refractory to standard treatment. Improving the quality of life and better pain relief is therefore an essential goal of the treatment of metastatic disease. The most common site of long bone metastases is the superior femoral epiphysis.

The usual management of patients with bone metastases in the superior femoral epiphysis is based on gamma implant osteosynthesis when there is a known risk of fracture (Mirels score> 8). Nonetheless this surgery is only accessible to a few patients because of the associated morbidities.

Percutaneous cementoplasty has been developed to treat patients who are not eligible for conventional surgery. It consists in a filling of the bone cavity created by metastasis using an acrylic resin. However, these approaches do not completely prevent the risk of upper femoral epiphyseal fracture due to the low mechanical resistance of the resin to shear movements.

The Y-STRUT® implantable medical device was developed to overcome this risk of superior femoral epiphyseal fracture by the biomechanical strengthening of the proximal femur in addition to cementoplasty. It has been successfully tested in more than 70 patients with cancer but access to reimbursement and the APHP market have been postponed due to lack of sufficient clinical evidence.

The investigators propose this prospective phase 2a study in order to provide evidence of the performance of the Y-STRUT® implant.


Description:

The design consists in a multicenter national open simple arm trial.

All eligible patients with a lytic bone metastases of the superior femoral epiphysis will be included.

The main objective of this study is to describe the impact of the Y-STRUT® implant on the quality of life of patients with lytic bone metastases of the femoral neck by comparing quality of life scores before and one month after the intervention of implantation of the implant.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 15
Est. completion date June 30, 2020
Est. primary completion date May 22, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- age >= 18 years

- patient with a lytic or mixed matrix bone metastasis of the superior femoral epiphysis visualized in imaging

- MIRELS score =8 within 20 days prior to inclusion,

- ECOG-PS 2 or 3 within 20 days prior to inclusion,

- Cervico-diaphyseal angle between 115 ° and 135 ° inclusive,

- Length of the proximal part of the femur greater than or equal to 90 mm

- Patient refusing gamma nail

- Life expectancy greater than 6 months

Exclusion Criteria:

- Act of general anesthesia impossible,

- ECOG <2 (patients eligible for nailing treatment),

- INR <0.7 in the 24 hours preceding the intervention,

- Platelets <70000 / mm3 within 24 hours of surgery,

- Allergy previously known by the patient to PEEK and / or PMMA,

- Patient who previously had a cementoplasty of the target lesion,

- Osteolysis of the target epiphyseal cortex> 2/3 of the circumference of the epiphyseal cortex,

- Pre-fracture lesions of the underlying ipsilateral diaphysis or ipsilateral acetabulum

- Patient unable or unwilling to give written consent.

Study Design


Intervention

Device:
Implantation
Implantation of Y-Strut + cementoplasty in the femoral neck

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris Hyprevention

Outcome

Type Measure Description Time frame Safety issue
Primary Measure of Quality of Life for each patient within one month after the implantation Measure of the Quality of Life score using the questionary of quality of life of the European Organization for Research and Treatment of Cancer BM-22.
Patients answer at 22 questions to describe their quality of life during the past week. For each question, patient must choose between 1.not at all, 2.a little, 3.enough, 4.a lot. A global score is calculated by adding the 22 score of each questions. The higher value of this global score represents the better outcome.
30 days
Secondary Target lesion fracture within one month after the implantation Number of target lesion fracture 30 days
Secondary Target lesion fracture within 2 months after the implantation Number of target lesion fracture 2 months
Secondary Non-target femoral fracture within 2 months after the implantation Number of Non-target femoral fracture 2 months
Secondary Non-target femoral fracture within one month after the implantation Number of Non-target femoral fracture 30 days
Secondary Analgesic medication needs (type and dose) within one month after the implantation Consumption of analgesic medication 30 days
Secondary Analgesic medication needs (type and dose) within 2 months after the implantation Consumption of analgesic medication 2 months
Secondary total AE/SAE within one month after the implantation Number of AE/SAE 30 days
Secondary total AE/SAE within 2 months after the implantation Number of AE/SAE 2 months
Secondary AE/SAE imputable to the device (number) within one month after the implantation Number of AE/SAE imputable to the device 30 days
Secondary AE/SAE imputable to the device (number) within 2 months after the implantation Number of AE/SAE imputable to the device 2 months
Secondary AE/SAE imputable to the implatation (number) within one month after the implantation Number of AE/SAE imputable to the implatation 30 days
Secondary AE/SAE imputable to the implatation (number) within 2 months after the implantation Number of AE/SAE imputable to the implatation 2 months
Secondary Morphinic mean dose per day within one month after the implantation Consumption of morphinic mean dose per day during the month after the procedure 30 days
Secondary Morphinic mean dose per day within 2 months after the implantation Consumption of morphinic mean dose per day during the 2 months after the procedure 2 months
Secondary Quality of Life score (EORTC QLQ BM-22) within 2 months after the implantation Measure of the Quality of Life score using the questionary of quality of life of the European Organization for Research and Treatment of Cancer BM-22.
Patients answer at 22 questions to describe their quality of life during the past week. For each question, patient must choose between 1.not at all, 2.a little, 3.enough, 4.a lot. A global score is calculated by adding the 22 score of each questions. The higher value of this global score represents the better outcome.
2 months
Secondary Pain score at target site within 2 months after the implantation: VAS Use of Visual Analog Scale (VAS) to evaluate the pain at target site (between 0: no pain to 10: intolerable pain) 2 months
Secondary Length of stay within 2 months after the implantation Length of stay at hospital 2 months
Secondary Exit mode of hospital within 2 months after the implantation at home, re-education unit 2 months
See also
  Status Clinical Trial Phase
Completed NCT02507609 - Deep Neuromuscular Block on Cytokines Release and Postoperative Delirium N/A
Completed NCT03906864 - Care Pathway for Sub-acute Hip Rehabilitation N/A
Recruiting NCT04063891 - Vibration Therapy as an Intervention for Enhancing Trochanteric Hip Fracture Healing in Elderly Patients N/A
Completed NCT05039879 - Life Improving Factors After a Hip Fracture
Terminated NCT03065101 - Trigen InterTAN vs Sliding Hip Screw RCT N/A
Completed NCT03695081 - Patient Pathway Pharmacist - Optimal Drug-related Care N/A
Completed NCT03545347 - Physiotherapy, Nutritional Supplement and Anabolic Steroids in Rehabilitation of Patients With Hip Fracture. Phase 2
Recruiting NCT05971173 - Nutritional Optimization and Bone Health Management for Older Adults Undergoing Hip Fracture Surgery Early Phase 1
Active, not recruiting NCT04957251 - Anterior vs Posterior Approach for Hip Hemiarthroplasty N/A
Terminated NCT04372966 - Uncemented Versus Cemented Total Hip Arthroplasty for Displaced Intracapsular Hip Fractures N/A
Withdrawn NCT05030688 - Fascia Iliaca Compartment Block and PENG Block for Hip Arthroplasty N/A
Completed NCT04424186 - 'Rehabilitation for Life' N/A
Not yet recruiting NCT04183075 - Impact of a Nutritional Supplement on the Recovery of the Nutritional Status of Patients With Spontaneous Hip Fracture N/A
Withdrawn NCT05518279 - Early Administration Of Tranexamic Acid And Acute Blood Loss In Patients With Hip Fractures Phase 3
Not yet recruiting NCT02892968 - ED Ultrasonographic Regional Anesthesia to Prevent Incident Delirium in Hip Fracture Patients N/A
Not yet recruiting NCT02223572 - Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture N/A
Active, not recruiting NCT02247791 - Uncemented Compared to Cemented Femoral Stems in Total Hip Arthroplasty N/A
Completed NCT00746876 - Unipolar or Bipolar Hemiarthroplasty in the Treatment of Displaced Femoral Neck Fractures. N/A
Completed NCT00058864 - The HIP Impact Protection Program (HIP PRO) N/A
Completed NCT05549011 - PENG vs SIFI Block for Positioning Pain During Spinal Anesthesia